H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Ligand Pharma (NASDAQ:LGND) on Monday, setting a price target of $310, which is approximately 173.90% above the present share price of $113.18.
Pantginis expects Ligand Pharma to post earnings per share (EPS) of $1.10 for the third quarter of 2021.
The current consensus among 2 TipRanks analysts is for a Moderate Buy rating of shares in Ligand Pharma, with an average price target of $250.
The analysts price targets range from a high of $310 to a low of $190.
In its latest earnings report, released on 03/31/2021, the company reported a quarterly revenue of $55.15 million and a net profit of $4.72 million. The company's market cap is $1.88 billion.
According to TipRanks.com, H.C. Wainwright analyst Joseph Pantginis is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 26.4% and a 45.23% success rate.
Ligand Pharmaceuticals , Inc. is a biopharmaceutical company, which engages in the development and acquisition of technologies that help pharmaceutical companies to discover and develop medicines. Its products include evomela, IV voriconazole, duavee, viviant/conbriza, nexterone, and noxafil-IV. The company was founded by Ronald M. Evans in 1987 and is headquartered in San Diego, CA.